Redeye views the Q2 report as a non-event since significant revenues should not come now, but later. We believe the sellers on the report were all “paper hands”, not really knowing when revenue will take off. As such, we believe this creates a good entry point.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.